Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?

Prepare for the ICH Good Clinical Practice (GCP) Exam for Certified Clinical Research Coordinator with engaging multiple-choice questions and detailed explanations. Elevate your understanding and expertise to excel in your certification exam!

Multiple Choice

Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?

Explanation:
When an unexpected serious adverse reaction occurs in a trial, it must be reported to both the regulatory authority and the IRB/IEC. Reporting to the regulatory authority flags a potential public-health risk and may prompt regulatory actions. Reporting to the IRB/IEC ensures ongoing ethics oversight, protecting participants and prompting any needed changes to the protocol or consent. The sponsor is part of the process, but the immediate recipients of such reportable events are the regulatory authority and the IRB/IEC.

When an unexpected serious adverse reaction occurs in a trial, it must be reported to both the regulatory authority and the IRB/IEC. Reporting to the regulatory authority flags a potential public-health risk and may prompt regulatory actions. Reporting to the IRB/IEC ensures ongoing ethics oversight, protecting participants and prompting any needed changes to the protocol or consent. The sponsor is part of the process, but the immediate recipients of such reportable events are the regulatory authority and the IRB/IEC.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy